Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome.

Biochemical pharmacology - 15 Oct 2015

Deutsch Stephen I, Burket Jessica A, Urbano Maria R, Benson Andrew D

Abstract excerpt

Currently, there are no medications that target core deficits of social communication and restrictive, repetitive patterns of behavior in persons with autism spectrum disorders (ASDs). Adults with Down syndrome (DS) display a progressive worsening of adaptive functioning, which is associated with Alzheimer's disease (AD)-like histopathological changes in brain. Similar to persons with ASDs, there are no effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha7 Nicotinic Acetylcholine Receptor
Share to Autism Spectrum Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down Syndrome

Share to Genetic Predisposition to Disease

Source

Identifiers

PMID: 26074265
DOI: 10.1016/j.bcp.2015.06.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome.PMID 26074265Read ↗

Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia.Semantic proximity Read ↗

A failure of β-amyloid physiological function due to genetic deletion of α7 nicotinic acetylcholine receptors induces an Alzheimer’s disease-like pathologySemantic proximity Read ↗

Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer’s DiseaseSemantic proximity Read ↗

Genetic deletion of α7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer’s disease-like pathologySemantic proximity Read ↗

Human disorders caused by the disruption of the regulation of excitatory neurotransmission.Semantic proximity Read ↗

Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors.Semantic proximity Read ↗

Emerging pharmacotherapies for neurodevelopmental disorders.Semantic proximity Read ↗

Long‐term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's diseaseSemantic proximity Read ↗

The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.Semantic proximity Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

Clinical, molecular, physiologic, and therapeutic feature of patients with CHRNA4 and CHRNB2 deficiency: A systematic review.Semantic proximity Read ↗

Neuronal nicotinic acetylcholine receptors: from the gene to the disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.